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The problems associated with medication use have long been recognized, including the impact of adverse 
drug events, the consequences of inappropriate medication use, and the burden of taking multiple 
medications as part of a complex, costly regimen.  General solutions to these challenges have seen the 
development of various standards, such as the Beer’s Criteria [1], and STOPP/START (screening tool of 
older people’s prescriptions/screening tool to alert to right treatment) criteria [2], to support prescribers in 
their decision-making.  These standards involve the identification and reduction of various medication-
related problems, including inappropriate medication use and potential drug-drug interactions.  Many 
studies have, to date, demonstrated the utility of these standards when applied to an elderly population, 
and have focused around reducing inappropriate medication amongst this group [3].   
 
Despite this success, it would appear that the utility of these standards is not directly transferable to all 
populations: improving the prescribing for patients with severe illness, advanced age, multi-morbidity, 
and diminishing life expectancy requires a different approach.  For example, if we consider statin therapy 
for primary or secondary prevention of cardiovascular disease: several cohort studies have shown that 
statin therapy is inappropriate among patients with advanced illness and subsequent diminished life 
expectancy [4,5].  Indeed, a recent controlled trial by Kutner and colleagues [6], who discontinued statin 
therapy in patients with an estimated life expectancy of between 1 month and 1 year, showed there was no 
significant difference in terms of mortality within 60 days of statin discontinuation compared to 
participants who continued their statins, suggesting it is safe to stop statins in the context of advanced 
illness.  Perhaps more significantly, however, in the same trial, patients who had their statin therapy 
discontinued appeared to have a significantly better quality of life.  If we consider this scenario using the 
Beer’s Criteria and STOPP/START criteria to support decision-making and assess medication 
appropriateness, statin therapy in this context would be considered ‘appropriate’.  Indeed, many 
preventive medications are considered appropriate and recommended for healthy older patients, but are 
considered inappropriate, or even ‘futile’ at the end of life [7].  
This dichotomy illustrates the challenges for prescribing medication for patients with diminished life 
expectancy, in which a ‘shift’ necessarily occurs in the medications that are rational and appropriate for 
an individual patient.  Predicting the timing of this shift and effectively discontinuing inappropriate 
medication for patients with diminished life expectancy is challenging – especially considering there is no 
clear guidance for those who make prescribing decisions.  
 
As a result of these challenges, several conceptual frameworks – used to prioritize medications late in life 
– have been developed [8-10].  These frameworks, although highly conceptual, consider the remaining 
life expectancy of the patient, and other factors, such as goals of care and time until benefit and offer a 
different approach to the conventional standards.  Indeed, several studies have used these frameworks and 
have demonstrated that many patients in end-of-life care continue to take medication that is no longer 
appropriate [7, 11-12].  At present, however, despite this evidence, there are still no incentives – or 
supportive guidance – to use or apply these conceptual frameworks in clinical practice.  This problem will 
continue until policy-makers feel compelled to prioritize medications late in life and offer appropriate 
guidance to healthcare professionals involved in medication use.  
 
Now is the time to address this problem.  Prescribing will only become more challenging due to the aging 
population, the burden of multi-morbidity, and restricted resources.  As the global population ages and 
more people present with multiple chronic conditions, applying more and more therapies on top of pre-
existing ones is not only not practical, it is burdensome and, in some cases harmful.  Furthermore, 
financial toxicity is increasingly recognized as an adverse consequence of treatment [13].  Even more 
challenging is the increasing number of guidelines focused on the initiation of medications, particularly 
those aimed at prevention.  For example, newer cholesterol guidelines in the United States recommend 
the initiation of statins for patients with lower cardiovascular risk than previously recommended, resulting 
in a projected increase from 38% to 87% in persons eligible for therapy [14]. Similarly, in the UK, NICE 
guidelines will incorporate a recommendation to start statin once a patient’s 10-year cardiovascular risk is 
estimated at 10% or greater, resulting in many more patients eligible for therapy. 
Even the guidelines for end-of-life care are focused on treating symptoms with more medication, rather 
than less [15]. However, healthcare providers who care for patients at the end of life are faced with real 
challenges in rationalizing medication use.  Another reason for the urgent need for guidance is the 
mandate to better streamline care at the end of life, such as the effort to consolidate the Medicare hospice 
and Part D prescription drug benefits [16-17]. It is apparent that the trend toward increasing medication 
use in later life cannot continue.  
 
Rather than adding more guidelines that advocate initiating more care, guidelines should directly address 
the appropriate removal of therapy. When looking for a model for such decisions, we turned to the 
challenges in using cardiac devices while planning for appropriate end-of-life care. We would argue that 
the principles of prescribing medication and using an implantable cardiac device are the same: the 
benefits must be continually balanced and assessed against the risks.  However, in the case of implantable 
cardiac devices, there is clear recognition that clinicians need guidance to explain how and when therapy 
should be stopped.  We, therefore, argue that rational prescribing and medication discontinuation in 
diminished life expectancy should be viewed through the same lens as the use of implantable cardiac 
devices in advanced heart failure [18].  
 
In this commentary we present five recommendations for rationalizing medication use, and propose that 
rationalizing medication use late in life should be incorporated into guidelines and considered an 
imperative for all healthcare providers – not just those that work in a specialist palliative care 
environment.  As the broader literature shows many patients are prescribed statins inappropriately late in 
life, and the recent trial by Kutner and colleagues [6], illustrating that statin discontinuation in patients 
with advanced illness resulted in an improved quality of life without impacting on survival, we discuss 
each recommendation in the view of statin therapy. 
 1) Shared decision-making is also about prescribing medications.  Prescribers have an ethical 
responsibility to involve patients in decision-making about medication use.  During a consultation 
about initiating a medication, healthcare professionals should be able to take the time required to have 
open discussions with patients about benefits and harms so that they can decide together whether a 
medication is a good option [19]. In the case of statins, the widespread use, promoted by new 
guidelines, means that many more people unlikely to benefit from statins will receive them.  
Discussing the decision to use a statin is important in this context. Ultimately, the prescribing of 
medications that are largely preventive based on such guidelines without shared decision-making is 
inherently paternalistic.  
2) Not prescribing a medication should be presented as a reasonable alternative for patients late in life, 
when appropriate.  Patients have the right to choose therapy from reasonable options.  Particularly in 
patients with limited life expectancy, the choice to not prescribe a medication, especially a preventive 
medication, is often a reasonable alternative.  This point illustrates the fact that for patients late in life, 
with advanced age, advanced illness, or multi-morbidity, many decisions will be preference-sensitive.  
Situations in which the risk-benefit ratio for different treatment options is unclear, a patient’s values, 
goals, and preferences should be prioritized to frame a prescribing decision.[16] In the case of a 
statin, there is a lack of evidence for substantial benefit for many subgroups of patients of advanced 
age or with multi-morbidity [20].  In this context, not prescribing a statin to a patient with diminished 
life expectancy is a reasonable choice given the current evidence base. 
3) Deprescribing is part of prescribing. Medications are burdensome interventions and, therefore, 
prescribing medications should always include a consideration of how long a therapy will be 
continued and when and how it should be discontinued.  Statin use should be accompanied by a 
consideration of when it would be no longer beneficial to a patient or when it could become 
burdensome.  A statin could be stopped when the time to benefit – defined as the time for a 
population to realize the intended effect of the medication – is longer than a patient’s estimated 
remaining life expectancy; this consideration should occur at the point of initial prescribing. 
4) Prescribers have to embrace uncertainty.  Prescribing involves estimation of benefits and harms, 
prognosis, and competing risks, and extrapolation of evidence to an individual clinical situation, all of 
which are inherently uncertain.  Reducing medication use should not be delayed until a poor 
prognosis is certain, such as when patients are referred to a palliative care team for specialist end of 
life care. Rather, when treating patients with diminishing life expectancy, clinicians should be more 
willing to embrace the uncertainty of stopping medications. In the case of statins, for example, 
prescribers will necessarily be unsure about stopping a statin, without being able to know a patient’s 
precise prognosis and cardiovascular risk. The uncertainty inherent in prescribing medications must 
be acknowledged and overcome. 
5) “Difficult discussions now will simplify difficult decisions in the future.”[18] This statement on 
cardiac devices in advanced heart failure captures the pertinence of this proposed approach when 
applied to prescribing.  When a medication is started, a discussion about when, why, and how to stop 
it should be initiated with the patient.  There should be a discussion about a patient’s current status 
and likely disease trajectory, and how the medication fits into a treatment plan given this anticipated 
trajectory and possible changes in goals of care.  When starting a preventive therapy like a statin, 
initiation of the medication should be framed in terms of overall health and disease risk.  A plan 
should be in place for when the statin is no longer part of the overall care plan.  When patients ask 
how long statins will be taken and clinicians respond, “for the rest of your life,” patients literally take 
this to mean that they will never stop the statin until the day they die.  This creates difficult decisions 
later for healthcare professionals providing end-of-life care, who are left explaining why patients 
should stop their statins. The time commitment involved in these initial discussions means that they 
may get deferred or never even happen.  In the context of other complex decisions, prescribing a 
preventative medication is easiest without a lengthy discussion.  
 
We articulate these five recommendations to illustrate that every healthcare professional has a role in the 
rationalizing of medications for patients late in life. The obligation to address appropriate medication use 
is not merely on the original prescriber; it is every prescriber’s responsibility to provide care that is 
consistent with patients’ goals, values, and preferences. 
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